As of close of business last night, Cardiff Oncology Inc’s stock clocked out at $5.73, up 7.30% from its previous closing price of $5.34. In other words, the price has increased by $+0.39 from its previous closing price. On the day, 876580 shares were traded.
Ratios:
To gain a deeper understanding of CRDF’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.41 and its Current Ratio is at 7.41. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 19 ’23 when PACE GARY W bought 30,000 shares for $1.37 per share. The transaction valued at 41,100 led to the insider holds 697,761 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 238.58M and an Enterprise Value of 165.90M. For the stock, the TTM Price-to-Sale (P/S) ratio is 522.48 while its Price-to-Book (P/B) ratio in mrq is 3.67. Its current Enterprise Value per Revenue stands at 339.96 whereas that against EBITDA is -3.69.
Stock Price History:
Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $0.94. The 50-Day Moving Average of the stock is 3.05, while the 200-Day Moving Average is calculated to be 1.86.
Shares Statistics:
It appears that CRDF traded 1.64M shares on average per day over the past three months and 1.34M shares per day over the past ten days. A total of 44.68M shares are outstanding, with a floating share count of 41.07M. Insiders hold about 8.07% of the company’s shares, while institutions hold 12.13% stake in the company. Shares short for CRDF as of Mar 15, 2024 were 2.81M with a Short Ratio of 1.71, compared to 1.19M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.30% and a Short% of Float of 6.48%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.23 and a low estimate of -$0.27, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.25, with high estimates of -$0.24 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.8 and -$1.06 for the fiscal current year, implying an average EPS of -$0.97. EPS for the following year is -$1.05, with 3 analysts recommending between -$0.8 and -$1.19.
